22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On August 30, 2019, California Governor Gavin Newsom signed Senate Bill (SB) 778 into law, thereby g...
Read More >
The World Health Organization has declared the 2019 novel coronavirus a global health emergency. Wit...
Read More >
His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the United ...
Read More >
In a well-publicized incident in 2017, Google terminated an employee who circulated a memorandum opp...
Read More >
On January 10, 2020 the United States Department of Justice (DOJ) and the Federal Trade Commission (...
Read More >
The U.S. Renewable Energy Industry, including its construction market, like every sector of the econ...
Read More >